StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners
July 28, 2017 10:31 AM
Leerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS Change
Analyst EPS View
Analyst PT Change
Next Articles
Bristol-Myers Squibb (BMY): IO Uncertainty Drives PT Decrease - BMO
July 28, 2017 7:01 AM
Bristol-Myers Squibb's (BMY) Call Didn't Alleviate Concerns - BMO
July 27, 2017 12:38 PM
Tech, transports drag on Wall Street; Dow hits record
July 27, 2017 7:35 AM
Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance
July 27, 2017 7:01 AM
Bristol-Myers Squibb Reports Second Quarter Financial Results
July 27, 2017 6:59 AM
Bristol-Myers Squibb (BMY) Falls Following Astra's Mystic Data; Merck (MRK) Gains
July 27, 2017 6:49 AM
Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1
July 26, 2017 6:59 AM
